-
Australia axe Labuschagne for Zimbabwe, South Africa ODI series
-
Top-seeded Zverev opens US Open campaign
-
Heavy rain at Grand Canyon after flood kills 2, dozen missing
-
US regulator, 22 states accuse Amazon of 'manipulating' ad auctions: lawsuit
-
Kushner blames soccer power struggle for World Cup plan collapse
-
TRON Founder Justin Sun Shares Outlook on Bitcoin, Stablecoins and Global Finance at Bitcoin Asia 2026
-
Buoyant Alcaraz shakes off nerves to advance at US Open
-
Tributes to 'eternal' Messi on Argentina retirement
-
US draws European pushback with Russia G20 finance invite
-
Arteta hails Arsenal's 'finishers' after Saka kills off Villa
-
Jury begins deliberations in Tupac Shakur murder trial
-
Yamal, Raphinha bag braces as Barcelona rout Rayo
-
US Supreme Court allows Trump ballroom project to proceed
-
Alcaraz makes winning return at US Open, Sabalenka safely through
-
Trump says US reviewing position on Falkland Islands
-
Everton agree to sign Monaco's Balogun: reports
-
Saka strikes as flawless Arsenal punish troubled Villa
-
Milei calls for F1 to return to Argentina
-
Oil prices surge on renewed fighting in US-Iran war
-
Alcaraz wins US Open first-round match after injury layoff
-
Cycling superstar Pogacar has surgery after Vuelta crash
-
Kyiv orders heightened security amid intense Russian drone strikes
-
Man City agree deal for Everton's Ndiaye
-
Sabalenka kickstarts US Open three-peat bid as Fils crashes out
-
Apple CEO Tim Cook gives nod to founder Steve Jobs in final memo
-
Fils upset by resurgent Tsitsipas at US Open
-
Russian finance minister makes unexpected appearance at G20
-
Trump says AI data center opponents want to be 'backwards and poor'
-
Happy to be back in NY, Sabalenka advances
-
Pakistan ditch coaches, send seven players home after England defeats
-
Naomi Watts to receive lifetime award at top Spain film fest
-
Galliano pulls Met Gala exhibit after antisemitism backlash
-
Jury hears closing arguments in Tupac Shakur murder trial
-
Afghan people should 'not be abandoned': top Red Cross official
-
Pakistan sack coach, send seven players home after England defeats
-
Six defining moments of Lionel Messi's Argentina career
-
New storms threaten Grand Canyon flood search, 2 bodies recovered
-
Trump blasts US backlash against data centers
-
France takes aim at ultra-fast fashion with new levy
-
It 'hurts' says Messi of decision to retire from international football
-
Tribunal says India cannot withdraw from water treaty with Pakistan
-
Benzema ends brief stint with Al Hilal in Saudi league
-
John Galliano pulls US exhibition after antisemitism backlash
-
Djokovic's Grand Slam future uncertain after brutal US Open defeat
-
French Top 14 boss offers 'no guarantees' for first Club World Cup
-
Turkey says regional defence pact not against any country
-
Munoz reunites with Glasner after joining Forest from Palace
-
US vows to keep economic pressure on Iran as G20 finance talks begin
-
Liverpool sign Barcola from PSG for £124 million
-
Shein valued at $26.3 bn in Hong Kong market debut
US drugmaker Eli Lilly says slashing insulin prices by 70%
US pharmaceutical giant Eli Lilly announced Wednesday it was cutting the cost of its most commonly prescribed insulins by 70 percent after years of soaring prices that hit millions of Americans living with diabetes.
The announcement comes as the cost of insulin has surged in recent years, with demand increasing significantly as well.
"Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system," the Indianapolis-based drugmaker said in a statement.
The company added it would cut the price of its non-branded insulin to $25 a vial starting May 1.
It will also lower the price of Humalog, its most commonly prescribed insulin, and Humulin, by 70 percent starting in the fourth quarter of this year.
"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change," said Lilly CEO David Ricks.
The company also said Wednesday it would automatically cap out-of-pocket costs at certain retail pharmacies at $35, for people with commercial insurance using Lilly insulin.
Diabetes is one of the fastest-growing chronic diseases globally, according to a 2022 study.
- Soaring prices -
In recent decades, insulin prices have soared in the United States, costing over eight times more than in 32 comparable high-income countries, a 2020 Rand Corporation study found.
But the cost of producing insulin is relatively low compared to the sale price.
A survey by nonprofit T1International also showed that one in four respondents living with diabetes reported rationing their insulin because of the financial strain.
In his State of the Union address last month, President Joe Biden said: "Big Pharma has been unfairly charging people hundreds of dollars –- and making record profits. Not anymore."
While seniors on Medicare have the cost of insulin capped, millions of other Americans not on the federal health insurance program for the elderly need insulin to save their lives, he added.
"Let's finish the job this time. Let's cap the cost of insulin at $35 a month for every American who needs it," Biden said.
Diabetes is divided into two types. An estimated nine million people have type 1 diabetes, a chronic condition where the pancreas does not produce enough insulin -- the hormone that regulates blood sugar levels.
Most people living with diabetes have type 2, which is associated with obesity and other lifestyle factors and emerges in adults and increasingly among children.
All type 1 diabetics need insulin to survive, and generally their access is ensured.
Some 63 million people with type 2 also need the hormone, according to World Health Organization estimates, but only about half of them can access it.
J.V.Jacinto--PC